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Abstract
Background: The esophageal cancer related gene 4 (ECRG4) was initially identified and cloned in our laboratory
from human normal esophageal epithelium (GenBank accession no.AF325503). ECRG4 was a new tumor suppressor
gene in esophageal squamous cell carcinoma (ESCC) associated with prognosis. In this study, we investigated the
novel tumor-suppressing function of ECRG4 in cancer cell migration, invasion, adhesion and cell cycle regulation in
ESCC.
Methods: Transwell and Boyden chamber experiments were utilized to examined the effects of ECRG4 expression
on ESCC cells migration, invasion and adhesion. And flow cytometric analysis was used to observe the impact of
ECRG4 expression on cell cycle regulation. Finally, the expression levels of cell cycle regulating proteins p53 and
p21 in human ESCC cells transfected with ECRG4 gene were evaluated by Western blotting.
Results: The restoration of ECRG4 expression in ESCC cells inhibited cancer cells migration and invasion (P < 0.05),
which did not affect cell adhesion capacity (P > 0.05). Furthermore, ECRG4 could cause cell cycle G1 phase arrest in
ESCC (P < 0.05), through inducing the increased expression of p53 and p21 proteins.
Conclusion: ECRG4 is a candidate tumor suppressor gene which suppressed tumor cells migration and invasion
without affecting cell adhesion ability in ESCC. Furthermore, ECRG4 might cause cell cycle G1 phase block possibly
through inducing the increased expression of p53 and p21 proteins in ESCC.
Introduction
Esophageal carcinoma ranks 7
th and 6
th in terms of can-
cer incidence and mortality rate worldwide, respectively
[1]. Moreover, nearly 50% of esophageal carcinoma
cases in the world occurred in China [2]. Esophageal
squamous cell carcinoma (ESCC), which is the most
common histological subtype, accounts for ~90% of all
esophageal cancers diagnosed in China each year.
Despite advances in clinical comprehensive treatment,
ESCC prognosis remains poor due to its diffuse and
invasive nature. To date, the molecular pathogenesis of
ESCC is still unclear [3,4].
The ECRG4 gene (GenBank accession no. AF325503)
was initially identified and cloned in our laboratory
from human normal esophageal epithelium [5,6]. Our
previous results demonstrated that ECRG4 protein was
an independent prognostic factor for ESCC, and the low
expression of ECRG4 protein in patients with ESCC was
associated with poor prognosis [7,8]. Furthermore, over-
expression of ECRG4 gene in ESCC cells inhibited
tumor cells growth in vitro and in vivo [7,8].
In the present study, we further examined the tumor-
suppressing function of ECRG4 gene, in terms of cell
migration and invasion, and explored possible molecular
mechanism in ESCC.
Materials and methods
Construction of eukaryotic expression vector and stable
transfection
The coding region of ECRG4 cDNA was subcloned into
constitutive mammalian expression vector pcDNA3.1
(Invitrogen). The cDNA was then fully sequenced to
ensure that no mutation was introduced during the PCR
amplification. The resulting plasmid construct was
* Correspondence: lilinweillw@yahoo.com.cn
1Oncology Department, Henan Provincial People’s Hospital, Zhengzhou
450003, PR China
Full list of author information is available at the end of the article
Li et al. Journal of Experimental & Clinical Cancer Research 2010, 29:133
http://www.jeccr.com/content/29/1/133
© 2010 Li et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.named pcDNA3.1-ECRG4. The human esophageal squa-
mous cell line EC9706 was established and studied by
Han et al [9]. EC9706 cells were seeded in 6-cm dishes
at 5×10
5 cells/dish and transfected with pcDNA3.1-
ECRG4 and pcDNA3.1 using lipofectamine™2000 (Invi-
trogen), according to the manufacturer’s protocol. After
culturing in medium containing 400 μg/ml of geneticin
(Invitrogen) for 3 weeks, individual clones were isolated.
Clones that expressed the ECRG4 cDNA coding region
were maintained in medium containing 200 μg/ml of
geneticin and used for further experiments.
Cell proliferation assay
EC9706 cells (pcDNA3.1 and pcDNA3.1-ECRGR4) were
seeded into 96-well plates (1.5 × 10
3 cells/well). After
culturing for various durations, cell proliferation was
evaluated by thiazolyl blue tetrazolium bromide (MTT)
assay, according to the manufacturer’s protocol (Sigma-
Aldrich Co., St. Louis, MO, USA). In brief, 10 μlM T T
solution (5 mg/ml) was added to each well, then the
cells were cultured for another 4 hours at 37°C, and
100 μl DMSO was added to each well and mix vigor-
ously to solubilize colored crystals produced within the
living cells. The absorbance at 570 nm was measured by
using a multi-well scanning spectrophotometer Victor 3.
In vitro cell migration and invasion assay
Cells growing in the log phase were treated with trypsin
and re-suspended as single-cell solutions. A total of 1 ×
10
5 cells in 0.5 ml of serum-free RPMI 1640 medium
were seeded on a 8 μm-pore polycarbonate membrane
Boyden chambers insert in a transwell apparatus(Costar,
Cambridge, MA), either coated with or without Matrigel
( B DB i o s c i e n c e s ,S a nJ o s e ,C A ) .6 0 0μlR P M I 1 6 4 0c o n -
taining 20% FBS was added to the lower chamber. After
the cells were incubated for 12-24 hours at 37°C in a 5%
CO2 incubator, cells on the top surface of the insert
were removed by wiping with a cotton swab. Cells that
migrated to the bottom surface of the insert were fixed
in 100% methanol for 2 minutes, stained in 0.5% crystal
violet for 2 min, rinsed in PBS and then subjected to
microscopic inspection (×200). Values for invasion and
migration were obtained by counting five fields per
membrane and represent the average of three indepen-
dent experiments.
Cell adhesion assay
Cells were plated on 100 ng/μl Matrigel-coated 96-well
plates at a density of 5 × 10
4 per well. The cells were
incubated at 37°C for 30, 60, and 90 minutes in a 5%
CO2 incubator, respectively. Nonattached cells were
removed by PBS washings for three times. Attached
cells were analyzed by 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium (MTS; Promega, Madison, WI) assay according to
the user manual. The mean absorbance values for statis-
tical analysis represent the average of three independent
experiments.
Western blot analysis
Whole-cell lysates of EC9706 cells were prepared by
incubating cells in RIPA buffer (1% NP-40; 0.5% sodium
deoxycholate; 0.1% SDS; 50 mM Tris-HCl [pH 7.5])
containing protease inhibitors. Cell lysates were centri-
fuged at 10,000 g for 10 minutes at 4°C. The superna-
tant was collected, and the protein concentration was
measured using the BCA ™ Protein Assay Kit (Pierce).
Proteins (40 ug) in cell lysates or culture media were
separated by 10-15% SDS-polyacrylamide gel electro-
phoresis and transferred onto PVDF membrane. The
membranes were blocked in TBST (0.2 M NaCl; 10 mM
Tris pH7.4; 0.2% Tween20)/5% skim milk for 2 hours at
room temperature and then incubated with primary
antibodies in TBST/5% skim milk. The primary antibo-
dies used for Western blot analysis were polyclonal
rabbit anti-ECRG4 (1:2000) [8], polyclonal rabbit anti-
p21(1:4000; Santa Cruz, CA), polyclonal rabbit anti-p53
(1:4000; Santa Cruz, CA), and monoclonal mouse anti-
b-actin (1:4000; Santa Cruz, CA). The membranes were
then washed three times with TBST, followed by incu-
bation with horseradish peroxidase-conjugated second-
ary antibody (1:4000) in TBST/5% skim milk. Bound
antibody was visualized using ECL detection reagent.
RT-PCR analysis
Cells were washed with PBS and collected for RT-PCR.
The primers designed for ECRG4 were 5’-GGT TCT
CCC TCG CAG CAC CT-3’ as forward and 5’-CAG
CGT GTG GCA AGT CAT GGT TAG-3’ as reverse.
Thermal cycles were: at 95°C for 2 min, then 30 cycles
at 95°C for 30 sec, at 62°C for 30 sec, at 72°C for 1 min
followed by extension at 72°C for 7 min [7].
Flow cytometric analysis of cell cycle
The transfected cells (pcDNA3.1-ECRG4 and
pcDNA3.1) were seeded at a density of 10
6 cells/100-
mm dish in RPMI-1640 medium with 10% FBS for
48 hours. Then cells were washed with ice-cold PBS,
harvested and fixed in 70% ethanol for 30 minutes. Cells
were treated with RNase A and stained with 25 μg/ml
propidium iodide (PI). Samples were analyzed using a
FACScan flow cytometer (Becton Dickinson), according
to the manufacturer’s protocol. Experiments were per-
formed three times in triplicate. The mean values for
statistical analysis represent the average of three inde-
pendent experiments.
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All statistical analysis was performed with the SPSS sta-
tistical program (version 13.0). Statistical significance
was determined using Student’s t-tests and analysis of
variance. P < 0.05 was considered statistically significant.
Results
ECRG4 overexpression suppressed cell migration and
invasion
The stable-transfected EC9706/pcDNA3.1-ECRG4 cells
exhibited detectable ECRG4 mRNA (Figure 1A) and
ECRG4 protein expression (Figure 1B), compared with
EC9706/pcDNA3.1 cells and EC9706 cells. And the cell
growth curve of EC9706/pcDNA3.1-ECRG4 and EC9706/
pcDNA3.1 was plotted for further migration-invasion ana-
lysis (Figure 1C). To measure the effect of ECRG4 overex-
pression on tumor cell migration, cells growing in the log
phase were collected and cultured on Transwell apparatus.
After 12 h incubation, cell migration was significantly
decreased in EC9706/pcDNA3.1-ECRG4 group than in
control group (P < 0.05) (Figure 2). Using Boyden cham-
ber precoated with Matrigel, we examined the effect of
ECRG4 overexpression on tumor cell invasion. After 24 h
incubation, EC9706/pcDNA3.1-ECRG4 cells showed sig-
nificantly decreased invasiveness, compared with the
EC9706/pcDNA3.1 cells (P < 0.05) (Figure 3). These
results demonstrated that ECRG4 overexpression reduced
the migration and invasion of ESCC cells.
The impact of ECRG4 overexpression on cell adhesion
capacity
As the apparent ECRG4-induced decrease in migra-
tion and invasion could be the result of reduction in
adhesion of tumor cells to the substrate, we evaluated
cell adhesive ability by measuring the number of cells
attached to Matrigel. No significant difference was
detected between the two groups by MTS adhesion
assay (P > 0.05) (Table 1). Therefore, ECRG4 overex-
pression in EC9706 cells drastically suppressed can-
cer cells mobility without affecting cell adhesion
capacity.
ECRG4 overexpression blocked cell cycle progression
The stable-transfected EC9706/pcDNA3.1-ECRG4 cells
exhibited detectable ECRG4 protein expression com-
pared with EC9706/pcDNA3.1 cells, as shown in
Figure 1B. The percentages of cells in the G1, S and
G2/M phase of cell cycle demonstrated that overex-
pression of ECRG4 in EC9706 cells resulted in an
accumulation of cells in G1 phase and a decrease in S
and G2/M phase compared with EC9706/pcDNA3.1
control cells (P < 0.05) (Table 2). Flow cytometric ana-
lysis suggested that ECRG4 overexpression could arrest
EC9706 cells at the G1/S checkpoint and delay cell
cycle into S phase. Consequently, ECRG4 overexpres-
sion slowed down cell cycle progression and caused
cell cycle G1 phase block.
Figure 1 Evaluation of ECRG4 gene expression and cell growth curve of EC9706/pcDNA3.1 and EC9706/pcDNA3.1-ECRG4.( A)E C R G 4
mRNA was detected in EC9706/pcDNA3.1-ECRG4 cells by RT-PCR. M: Marker; Lane 1: EC9706/pcDNA3.1; Lane 2: EC9706/pcDNA3.1-ECRG4; Lane 3:
EC9706 cells. (B) ECRG4 protein (17 KD) was detected in EC9706/pcDNA3.1-ECRG4 cells by Western blot. Lane 1: EC9706 cells; Lane 2: EC9706/
pcDNA3.1; Lane 3: EC9706/pcDNA3.1-ECRG4. (C) Cell growth curve of EC9706/pcDNA3.1 and EC9706/pcDNA3.1-ECRG4 by MTT assay (P < 0.05).
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In exploring the molecular mechanism of cell cycle G1
phase block caused by ECRG4 overexpression in
EC9706 cells, we found that p53 and p21 protein
expression levels were increased in EC9706/pcDNA3.1-
ECRG4 cells compared with in EC9706/pcDNA3.1 cells
(Figure 4). It indicated that ECRG4 may be involved in
p53 pathway in ESCC. ECRG4 might induce p21 upre-
gulation through p53 pathway to block cell cycle pro-
gression in ESCC.
Discussion
ESCC is a highly invasive and clinically challenging can-
cer in China, and its molecular basis remains poorly
Figure 2 Effect of ECRG4 overexpression on tumor cells migration. Representative photos and statistic plots of migration assay in EC9706/
pcDNA3.1-ECRG4 and EC9706/pcDNA3.1 cells (×200). The number of EC9706/pcDNA3.1-ECRG4 cells transversed the Transwell membrane was
decreased compared with that of EC9706/pcDNA3.1 cells (P < 0.05). Error bars represent standard deviation from mean value.
Figure 3 Effect of ECRG4 overexpression on tumor cells invasion. Representative photos and statistic plots of invasion assay in EC9706/
pcDNA3.1-ECRG4 and EC9706/pcDNA3.1 cells (×200). The number of EC9706/pcDNA3.1-ECRG4 cells transversed the Transwell membrane was
decreased compared with that of EC9706/pcDNA3.1 cells (P < 0.05). Error bars represent standard deviation from mean value.
Table 1 ECRG4 exerted no significant effect on tumor
cells adhesion capacity
Group 30 min 60 min 90 min
EC9706/pcDNA3.1-ECRG4* 1.268 ± 0.293 1.988 ± 0.341 2.564 ± 0.537
EC9706/pcDNA3.1 1.274 ± 0.247 2.040 ± 0.360 2.531 ± 0.524
* P > 0.05, compared with EC9706/pcDNA3.1.
Table 2 ECRG4 overexpression caused cell cycle G1 phase
block
Group G1 S G2/M
EC9706/pcDNA3.1-ECRG4* 73.7 ± 1.86 14.8 ± 1.13 11.5 ± 0.92
EC9706/pcDNA3.1 59.8 ± 2.06 25.0 ± 1.39 15.2 ± 1.64
* P < 0.05, compared with EC9706/pcDNA3.1.
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in our laboratory [5,6]. ECRG4 gene is highly conserved
among various species, suggesting an important role for
ECRG4 in eukaryotic cells [10]. However, its exactly
biological function in carcinogenesis is still unclear. Our
previous study demonstrated that ECRG4 gene promoter
hypermethylation accounted for decreased expression in
ESCC, and the low expression of ECRG4 protein in
patients with ESCC was associated with poor prognosis
[7,8]. These findings were also supported by similar stu-
dies of other research groups [11,12]. Furthermore,
restoration of ECRG4 expression in ESCC cells inhibited
tumor cells growth in vitro and in vivo [7,8].
In this study, we revealed a novel function of ECRG4
that suppressed tumor cells migration and invasion
without affecting cell adhesion ability in ESCC, implicat-
ing its potential involvement in tumor development.
Li et al [13] observed the similar result in glioma consis-
tent with ours. Enhancement in motility and loss of
adhesion capacity are advantageous to tumor invasion,
which is one main mechanism to cause cancer metasta-
sis. Transformed cells acquire a series of additional
malignant traits, such as invasion and metastasis abil-
ities, during tumorigenesis and progression.
It is now generally accepted that transcription factor
NF-B and COX-2 pathway plays a central role between
inflammation and carcinogenesis [14,15]. Recently, NF-
B and COX-2 were approved to promote tumor cells
migration and invasion [16-23]. Our previous results
showed that ECRG4 attenuated NF-B expression and
nuclear translocation and reduced NF-Bt a r g e tg e n e
COX-2 expression in ESCC [8]. Li et al [13] also
observed that ECRG4 transfection decreased NF-B
expression in glioma. Therefore, we speculated that NF-
B pathway might be involved in ECRG4-induced
decrease of tumor cells migration and invasion in ESCC.
However, the detailed molecular mechanism remained
to be clarified in subsequent research.
The cell cycle alteration plays a major role in carcino-
genesis. Once the cell cycle regulation balance was bro-
ken, it might result in tumorigenesis. Evidence has
revealed that many oncogenes and tumor suppressor
genes are directly involved in regulation of cell cycle
events [24]. In the present research, we discovered for
the first time that ECRG4 inhibited cancer cells prolifera-
tion and induced cell cycle G1 phase block by up-regulat-
ing p21 expression level through p53 mediated pathway
in ESCC. It is well known that p21, the critical cyclin-
dependent kinase inhibitor, is able to block the cell cycle
at G1 phase [25,26]. So the p21 expression upregulation
could be the molecular mechanism for the ECRG4-
induced cell cycle G1 phase block in ESCC.
Taken together, ECRG4 is a candidate tumor suppres-
sor gene which suppressed cancer cells migration and
invasion in ESCC. Furthermore, ECRG4 could also
cause cell cycle G1 phase block through the upregula-
tion of p53 and p21 expression levels. Our study indi-
cated that loss of ECRG4 function might play a pivotal
role in ESCC carcinogenesis and implied that ECRG4
could be an important therapeutic target for ESCC.
Abbreviations
ECRG4: esophageal cancer related gene 4; ESCC: esophageal squamous cell
carcinoma; NF-B: NF-kappaB; COX-2: cyclooxygenase 2; GAPDH:
glyceraldehyde-3-phosphate dehydrogenase; PBS: phosphate-buffered saline;
RT-PCR: reverse transcriptase-polymerase chain reaction.
Acknowledgements
This work was supported by the Chinese State Key Projects for Basic
Research (2002CB513101 and 2004CB518701) and the Henan Province
Science Research Key Project (0624410058). We thank professor Wei Jing of
Burnham Institute Cancer Center (La Jolla, CA92037, USA) for helpful
comments on this manuscript. We also thank Dr Xiao-chun Wang and Dr
Hong-yan Chen for the technical assistance.
Author details
1Oncology Department, Henan Provincial People’s Hospital, Zhengzhou
450003, PR China.
2State Key Laboratory of Molecular Oncology and
Department of Etiology and Carcinogenesis, Cancer Institute & Hospital,
Figure 4 ECRG4 may be involved in p53 pathway. Representative photos and statistic plots of relative protein expression levels in EC9706/
pcDNA3.1-ECRG4 and EC9706/pcDNA3.1. Analysis of cell’s total proteins by Western blot showed that p53 and p53 target gene p21 expressions
were increased in EC9706/pcDNA3.1-ECRG4 cells compared with in EC9706/pcDNA3.1 cells (P < 0.05). Lane 1: EC9706/pcDNA3.1-ECRG4; Lane 2:
EC9706/pcDNA3.1. *, P < 0.05, compared with EC9706/pcDNA3.1.
Li et al. Journal of Experimental & Clinical Cancer Research 2010, 29:133
http://www.jeccr.com/content/29/1/133
Page 5 of 6Chinese Academy of Medical Sciences & Peking Union Medical College,
Beijing 100021, PR China.
Authors’ contributions
LL carried out cell culture, gene transfection, gene functional assays, RT-PCR
and Western blotting. CZ and XL analyzed and interpreted data. YZ and SL
supervised experimental and wrote the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 August 2010 Accepted: 11 October 2010
Published: 11 October 2010
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA
Cancer J Clin 2005, 55:74-108.
2. Holmes RS, Vaughan TL: Epidemiology and pathogenesis of esophageal
cancer. Semin Radiat Oncol 2007, 17:2-9.
3. Luo A, Kong J, Hu G, Liew CC, Xiong M, Wang X, Ji J, Wang T, Zhi H, Wu M,
Liu Z: Discovery of Ca2+-relevant and differentiation-associated genes
downregulated in esophageal squamous cell carcinoma using cDNA
microarray. Oncogene 2004, 23:1291-1299.
4. Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Imamura M,
Sugano S, Nakamura Y, Inazawa J: Identification of a novel gene, GASC1,
within an amplicon at 9p23-24 frequently detected in esophageal
cancer cell lines. Cancer Res 2000, 60:4735-4739.
5. Bi MX, Han WD, Lu SX: Using Lab On-line to Clone and Identify the
Esophageal Cancer Related Gene 4. Sheng Wu Hua Xue Yu Sheng Wu Wu
Li Xue Bao(Shanghai) 2001, 33:257-261.
6. Su T, Liu H, Lu S: Cloning and identification of cDNA fragments related
to human esophageal cancer. Chin J Oncol 1998, 20:254-257.
7. Yue CM, Deng DJ, Bi MX, Guo LP, Lu SH: Expression of ECRG4, a novel
esophageal cancer-related gene, downregulated by CpG island
hypermethylation in human esophageal squamous cell carcinoma. World
J Gastroenterol 2003, 9:1174-1178.
8. Li LW, Yu XY, Yang Y, Zhanag CP, Guo LP, Lu SH: Expression of
esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor
gene, in esophageal cancer and its inhibitory effect on the tumor
growth in vitro and in vivo. Int J Cancer 2009, 125:1505-1513.
9. Han Y, Wei F, Xu X, Cai Y, Chen B, Wang J, Xia S, Hu H, Huang X, Han Y,
Wu M, Wang M: Establishment and comparative genomic hybridization
analysis of human esophageal carcinomas cell line EC9706. Zhonghua Yi
Xue Yi Chuan Xue Za Zhi 2002, 19:455-457.
10. Steck E, Breit S, Breusch SJ, Axt M, Richter W: Enhanced expression of the
human chitinase 3-like 2 gene (YKL-39) but not chitinase 3-like 1 gene
(YKL-40) in osteoarthritic cartilage. Biochem Biophys Res Commun 2002,
299:109-115.
11. Mori Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, Mori R,
Tomoda K, Ogawa R, Katada T, Harata K, Fujii Y: Expression of ECRG4 is an
independent prognostic factor for poor survival in patients with
esophageal squamous cell carcinoma. Oncol Rep 2007, 18:981-985.
12. Götze S, Feldhaus V, Traska T, Wolter M, Reifenberger G, Tannapfel A,
Kuhnen C, Martin D, Műller O, Sievers S: ECRG4 is a candidate tumor
suppressor gene frequently hypermethylated in colorectal carcinoma
and glioma. BMC Cancer 2009, 9:447-457.
13. Li W, Liu XR, Zhang B, Qi DX, Zhang LH, Jin YH, Yang HF: Overexpression
of candidate tumor suppressor ECRG4 inhibits glioma proliferation and
invasion. J Exp Clin Cancer Res 2010, 29:89-95.
14. Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent
bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
15. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-
Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a
tumor promoter in inflammation-associated cancer. Nature 2004,
431:461-466.
16. Wu CY, Wang CJ, Tseng CC, Chen HP, Wu MS, Lin JT, Inoue H, Chen GH:
Helicobacter pylori promote gastric cancer cells invasion through a NF-
kappaB and COX-2-mediated pathway. World J Gastroenterol 2005,
11:3197-3203.
17. Liu Q, Chen T, Chen G, Shu X, Sun A, Ma P, Lu L, Cao X: Triptolide impairs
dendritic cell migration by inhibiting CCR7 and COX-2 expression
through PI3-K/Akt and NF-kappaB pathways. Mol Immunol 2007,
44:2686-2696.
18. Takaoka K, Kishimoto H, Segawa E, Hashitani S, Zushi Y, Noguchi K,
Sakurai K, Urade M: Elevated cell migration, invasion and tumorigenicity
in human KB carcinoma cells transfected with COX-2 cDNA. Int J Oncol
2006, 29:1095-1101.
19. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H,
Wirth T: NF-kappaB promotes epithelial-mesenchymal transition,
migration and invasion of pancreatic carcinoma cells. Cancer Lett 2010,
295:214-228.
20. Wu Y, Zhou BP: TNF-alpha/NF-kappaB/Snail pathway in cancer cell
migration and invasion. Br J Cancer 2010, 102:639-644.
21. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP: Stabilization of
snail by NF-kappaB is required for inflammation-induced cell migration
and invasion. Cancer Cell 2009, 15:416-428.
22. Ho YT, Yang JS, Li TC, Lin JJ, Lin JG, Lai KC, Ma CY, Wood WG, Chung JG:
Berberine suppresses in vitro migration and invasion of human SCC-4
tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-
kappaB, u-PA and MMP-2 and -9. Cancer Lett 2009, 279:155-162.
23. Niu J, Chang Z, Peng B, Xia Q, Lu W, Huang P, Tsao MS, Chiao PJ:
Keratinocyte growth factor/fibroblast growth factor-7-regulated cell
migration and invasion through activation of NF-kappaB transcription
factors. J Biol Chem 2007, 282:6001-6011.
24. Lu SH: Alterations of oncogenes and tumor suppressor genes in
esophageal cancer in China. Mutat Res 2000, 462:343-353.
25. Whitson JM, Noonan EJ, Pookot D, Place RF, Dahiya R: Double stranded-
RNA-mediated activation of P21 gene induced apoptosis and cell cycle
arrest in renal cell carcinoma. Int J Cancer 2009, 125:446-452.
26. Liu F, Li X, Wang C, Cai X, Du Z, Xu H, Li F: Downregulation of p21-
activated kinase-1 inhibits the growth of gastric cancer cells involving
cyclin B1. Int J Cancer 2009, 125:2511-2519.
doi:10.1186/1756-9966-29-133
Cite this article as: Li et al.: The candidate tumor suppressor gene
ECRG4 inhibits cancer cells migration and invasion in esophageal
carcinoma. Journal of Experimental & Clinical Cancer Research 2010 29:133.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. Journal of Experimental & Clinical Cancer Research 2010, 29:133
http://www.jeccr.com/content/29/1/133
Page 6 of 6